Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

(2022) Christopher JL Murray et al.   LANCET

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

(2022) Marco Falcone et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

(2022) Amanda Vivo et al.   BMC INFECTIOUS DISEASES

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021

(2022) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States

(2021) Richard E Nelson et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

(2021) Mical Paul et al.   CLINICAL MICROBIOLOGY AND INFECTION

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

(2021) Thomas P. Lodise et al.   Expert Review of Anti-Infective Therapy

Safety, Pharmacokinetics, and Drug:Drug Interaction Potential of Intravenous Durlobactam, a β-lactamase Inhibitor, in Healthy Subjects

(2020) Jason D. Lickliter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

(2020) Qiwen Yang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

(2019) Olexiy Sagan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

(2017) Thomas F. Durand-Réville et al.   Nature Microbiology

Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections

(2016) E. Durante-Mangoni et al.   CLINICAL MICROBIOLOGY AND INFECTION

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

(2015) William F. Penwell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

(2014) Rujipas Sirijatuphat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

(2013) Emanuele Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center

(2009) Joshua D. Hartzell et al.   CLINICAL INFECTIOUS DISEASES

Definition and Classification of Acute Kidney Injury

(2008) John A. Kellum et al.   NEPHRON CLINICAL PRACTICE